Factors favouring long-term survival following recurrence in ovarian cancer

Soyama, Hiroaki; Takano, Masashi; Miyamoto, Morikazu; Yoshikawa, Tomoyuki; Aoyama, Tadashi; Gotō, Tomoko; Hirata, Junko; Suzuki, Ayako; Sasa, Hidenori; Furuya, Kenichi

doi:10.3892/mco.2017.1266

Cited by 7 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the current first-line treatment paradigm for newly diagnosed ovarian cancer patients is initially effective in 70–80% of cases, most patients will relapse 1 and fewer than half of all women diagnosed with ovarian cancer will survive beyond five years 2 . Overall survival may be prolonged by lengthening the time to initial progression as this time interval has an impact upon clinical treatment and response 3–5 . There are no biomarkers currently available to accurately predict patient response to first- or second-line therapy, hampering efforts to increase overall survival by this strategy.…”

Section: Introductionmentioning

confidence: 99%

Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer

Shuford

Wilhelm

Rayner

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Although 70–80% of newly diagnosed ovarian cancer patients respond to first-line therapy, almost all relapse and five-year survival remains below 50%. One strategy to increase five-year survival is prolonging time to relapse by improving first-line therapy response. However, no biomarker today can accurately predict individual response to therapy. In this study, we present analytical and prospective clinical validation of a new test that utilizes primary patient tissue in 3D cell culture to make patient-specific response predictions prior to initiation of treatment in the clinic. Test results were generated within seven days of tissue receipt from newly diagnosed ovarian cancer patients obtained at standard surgical debulking or laparoscopic biopsy. Patients were followed for clinical response to chemotherapy. In a study population of 44, the 32 test-predicted Responders had a clinical response rate of 100% across both adjuvant and neoadjuvant treated populations with an overall prediction accuracy of 89% (39 of 44, p < 0.0001). The test also functioned as a prognostic readout with test-predicted Responders having a significantly increased progression-free survival compared to test-predicted Non-Responders, p = 0.01. This correlative accuracy establishes the test’s potential to benefit ovarian cancer patients through accurate prediction of patient-specific response before treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer

Shuford

Wilhelm

Rayner

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Time to relapse is an important prognostic factor in ovarian cancer as subsequent chemoresponse is based on this time interval. 3 In the doctrines of Ayurveda, the clinical stages and treatments for benign and malignant tumors have been discussed in detail. 4 Rasayana chikitsa is one of the therapeutic segments of Ayurveda, which helps to improve immunity, consists of compounds having immune-stimulant, immune-modulator effects and hence they restore health.…”

Section: Introductionmentioning

confidence: 99%

“…Time to relapse is an important prognostic factor in ovarian cancer as subsequent chemoresponse is based on this time interval. 3…”

Section: Introductionmentioning

confidence: 99%

Ayurveda Maintenance Therapy in Recurrent Ovarian Cancer

Wanjarkhedkar

Kulkarni

Hingmire

et al. 2022

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Despite optimal surgery and first-line platinum-based doublet chemotherapy, approximately 70 to 80% of patients with epithelial ovarian cancers relapse. Two cases of recurrent ovarian cancer (ROC) were treated with non–platinum-based Ayurveda maintenance therapy (AMT) consisting of drugs having a herbal and herbomineral origin. This regimen was followed over a period of 3 years and progression-free survival (PFS) was noted along with platinum-free interval (PFI). Two patients were diagnosed with BRCA1 mutated recurrent high-grade serous ovarian carcinoma and treated with the per-oral AMT regimen labeled as ZINCA-30 in our hospital after completion of standard of care treatment and followed up until progression. The ZINCA-30 regimen comprising Jasada (traditional Zinc preparation), Indukanth kwatham and Curcuma amada powder in combination was prescribed based on Rasayana chikitsa postulated in Ayurveda. The patients were followed up every 3 months. The progression-free survival observed in these patients was 28 months and 36.3 months, respectively. These two pilot cases suggested an increased platinum-free interval (PFI), improved progression-free survival (PFS) in recurrent ovarian cancer (ROC), with the AMT labeled as ZINCA-30 after chemotherapy.

show abstract

“…In most patients with advanced EOC, cancer reoccurs repeatedly with progressively shorter progression-free intervals and repeated chemotherapy. Treatment after recurrence is ineffective, with a median survival of 2 years after recurrence [ 2 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…Secondary cytoreductive surgery is one of the factors associated with the 5-year survival after recurrence [ 2 6 ]. Recently, 3 RCTs have reported inconsistent survival outcomes of secondary cytoreductive surgery in platinum-sensitive recurrent EOC patients predicted to have potentially resectable disease [ 36 37 38 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines

Lee,

Chang,

Kwon

et al. 2024

J Gynecol Oncol

View full text Add to dashboard Cite

Since the latest practice guidelines for ovarian cancer were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2021, many studies have examined the efficacy and safety of various treatments for epithelial ovarian cancer (EOC). Therefore, the need to develop recommendations for EOC treatments has been raised. This study searched the literature using 4 key items and the Population, Intervention, Comparison, and Outcome: the efficacy and safety of poly-ADP ribose polymerase inhibitors in newly diagnosed advanced EOC; the efficacy and safety of intraperitoneal plus intravenous chemotherapy in optimally debulked advanced EOC; the efficacy and safety of secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer; and the efficacy and safety of the addition of bevacizumab to platinum-based chemotherapy in first platinum-sensitive recurrent EOC patients who received prior bevacizumab. The evidence for these recommendations, according to each key question, was evaluated using a systematic review and meta-analysis. The committee of ovarian cancer of the KSGO developed updated guidelines for treatments of EOC.

show abstract

Factors favouring long-term survival following recurrence in ovarian cancer

Cited by 7 publications

References 20 publications

Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer

Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer

Ayurveda Maintenance Therapy in Recurrent Ovarian Cancer

Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines

Contact Info

Product

Resources

About